There are references today to Tom Brady, Mark Cuban, and PBM concentration. Something for everyone!
And PCMA has picked up the pace of its communications, so Cost Curve is going to have to pick up the pace of its fact-checking
Plus obesity news on adherence, vials, and reimbursement in Medicare
And a survey of community oncologists finds near unanimity on the negative impacts of step therapy
And the Trump administration says that it has successfully pushed prices up in Europe, though the evidence of pricing action overseas remains scant
And there are still TrumpRx stories to be told, including an effort by Pfizer to use the platform in a low-key biosimilar price war
And Hims announced a compounded version of Wegovy’s active ingredient, causing reactions from Novo and the FDA
And Express Scripts settles with the FTC, with the PBM promising to fundamentally change its business practices
But today big stories all involve obesity-med dynamics, and I’ll go deep there in tomorrow’s Apex
PBM reform is getting close to the congressional finish line, but questions remain about the impact
And it’s a quiet day -- but probably a noisy week -- when it comes to drug-pricing news
And the White House wants Congress to codify its MFN policies. Republicans are (appropriately) skeptical.
And there’s reporting that the launch of TrumpRx is imminent, though questions persist
And HHS is working to identify and limit legal risks around TrumpRx and other pharm-to-table programs
And hospitals strike back as Lilly moves to require more data from in-house pharmacies at 340B providers
And the PBM reform timeline may slip as the Minneapolis killing scrambles legislative efforts on spending bills
But the Cigna CEO makes a notable disclosure about the cost of moving away from drug rebates
And a sampling of the best LinkedIn health policy content from the past week or so
And HEOR leaders assess how pharma strategies will change in light of IRA, MFN pressures
And legislative language laying out PBM reform is released by congressional negotiatorsPlus thinking on the revelations and limitations of list- and net-price disclosures
And SureScripts and GoodRx are teaming up to give patients real-time info on what their meds will cost
And a new resource from J&J underscores the need to protect the U.S. patent system
And AbbVie joins the long list of companies that have struck deals with the White House
And early evidence of how the $2,000 out-of-pocket cap is helping patients ... and where it’s falling short
And list prices are falling on medicines that generated a total of $50 billion in sales last year
